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Abstract 
Membrane-type matrix metalloproteinases (MT-MMPs) have attracted strong attention, because four of them can 
activate a key player in the tumor scenario, proMMP-2/progelatinase A. In addition to this indirect effect on the 
cellular environment, these MT-MMPs degrade extracellular matrix proteins, and their overproduction is 
associated with tumor growth. We have solved the structure of the catalytic domain (cd) of MT3-MMP/MMP-16 
in complex with the hydroxamic acid inhibitor batimastat. CdMT3-MMP exhibits a classical MMP-fold with 
similarity to MT1-MMP Nevertheless, it also shows unique properties such as a modified MT-specific loop and 
a closed S1' specificity pocket, which might help to design specific inhibitors. Some MT-MMP-specific features, 
derived from the crystal structures of MT-1-MMP determined previously and MT3-MMP, and revealed in recent 
mutagenesis experiments, explain the impaired interaction of the MT-MMPs with TIMP-1. Docking experiments 
with proMMP-2 show some exposed loops including the MT-loop of cdMT3-MMP involved in the interaction 
with the proMMP-2 pro-domain in the activation encounter complex. This model might help to understand the 
experimentally proven importance of the MT-loop for the activation of proMMP-2. 
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INTRODUCTION 
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases, which are capable of collectively 
degrading all kinds of extracellular matrix proteins, but also can process a number of bioactive molecules.1 The 
MMPs play an important role in tissue remodeling associated with various physiological and pathological 
processes such as morphogenesis, angiogenesis, tissue repair, arthritis and tumor invasion.2-6 According to their 
cellular localization, the 23 human MMPs can be subdivided into 16 secreted and seven membrane bound 
MMPs. The latter MMPs include (i) the type-II transmembrane cysteine array MMP-23,7,8 (ii) the glycosyl 
phosphatidylinositol-attached MMPs 17 and 25/membrane-type MT-MMPs 4 and 6,9,10 and (iii) the type-I 
transmembrane MMPs 14, 15, 16, and 24/MT-MMPs 1, 2, 3, and 5.11 In addition, some secreted MMPs such as 
(pro)MMP-2 are recruited to and activated at the cell surface to make focal proteolysis.12 It has been proposed 
that this surface binding (e.g. via integrin interaction) might allow the fine control of ECM degradation near the 
cell surface of tumor cells.13 On the other hand, the location of membrane-type MMPs at the plasma membrane 
situates them in a position suitable to promote tumor invasion. 
The MT-MMPs 1, 2, 3 and 5 play a dual role in cell surface proteolysis, in that they are able to cleave a variety 
of extracellular matrix components in vitro and to shed membrane-bound receptors,14 but are also capable of 
activating proMMP-2 (pro-gelatinase A).11 MT1-MMP seems to be the major activator of proMMP-2, mainly via 
presentation of proMMP-2 by a MT1-MMP-TIMP-2 "receptor".15-18 However, the catalytic domains or the full-
length molecules of the other MT-MMPs19-23 have also been shown in vitro or expressed in mammalian cells, 
respectively, to activate proMMP-2. Apparently, MT2-MMP is able to perform this activation  in  a  TIMP-2-
independent  manner.24  The proMMP-2 activation ability has been associated with a characteristic loop insertion 
(the MT-specific loop)25 between strands sII and sIII of the catalytic domain,26 and, accordingly, the inefficiency 
in proMMP-2 activation of the classical MMPs and MT-MMPs 427 and 628,29 with the lack of this loop. The more 
severe phenotype exhibited by MT1-MMP knock-out mice compared with MMP-2 deficient mice30,31 indicates, 
however, that the MT-MMPs 1, 2, 3 and 5 play a much broader role than simply to activate proMMP-2.  
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Figure 1. (a) Ribbon plot of cdMT3-MMP (yellow) displayed in stereo view (standard orientation). CdMT3-MMP, shown together with the 
bound batimastat inhibitor, is superimposed with the catalytic domains of MMP-1 (PDB accession code 1CGL), MMP-3 (1UEA), MMP-7 
(1MMP), MMP-8 (1JAN), MMP-11 (1HV5), MMP-12 (1JK3), MMP-13 (456C), MMP-14 (1BQQ, pink), and MMP-2 (1QIB) and MMP-9 
(1GKC) with the fibronectin type II repeats deleted. The catalytic and the structural zinc ion and the two bound calcium ions are displayed as 
pink and green spheres, respectively. The three His residues liganding the catalytic zinc and the characteristic Met264 are shown with all 
non-hydrogen atoms. The MT-loops of MT1-MMP and MT3-MMP significantly protrude away from the molecular surface compared with 
the sII-sIII bridges of the other MMPs. The Figure was made with BOBSCRIPT73 and Raster3D74. (b) and (c) Solid surface representation of 
the catalytic domain of MT3-MMP (b) and MT1-MMP (c) (1bqq). The molecules are shown in their front view in stereo (standard 
orientation), with a proMMP-2 derived Ser-Cys-Asn*Leu-Phe-Val heptapeptide modelled into their active-site clefts. The coloring of the 
surface is according to the calculated negative and positive electrostatic potentials contoured from -10 kT/e (red) to +10 kT/e (blue). 
Noteworthy are the different shapes and charge distributions of the exposed MT-specific loops (left upper edge of the molecules). The Figure 
was made with Swiss-PDBViewer*75 and POV-Ray/MegaPov†. (d) Alignment of the MT3-MMP catalytic domain sequence with the catalytic 
domain sequences of other MMPs of known molecular structure, based on topological equivalence. Residues involved in binding of the 
catalytic and the structural zinc and of the two to three (in a few other MMPs) calcium ions are marked with Z1, Z2, C1, C2 and C3, and 




                                                          
* http://www.expasy.org/spdbv/ 
† POV-RAY (http://povray.org) and MegaPov (http:// nathan.kopp.com/patched.htm) 
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While MT-MMPs 1 and 2 are expressed in a variety of adult human tissues, expression of the MT-MMPs 3 and 
5 seems to be restricted normally to the brain and the heart.21,32,33 MT3-MMP, like MT1-MMP, is highly 
expressed in cancerous tissues compared with normal tissues. It has been found in renal carcinoma,34 astrocytic 
tumors33 and melanoma,32 while it was not detected in breast and thyroid carcinomas, which expressed MT1-
MMP35 MT3-MMP has been shown to possess the potential to promote melanoma invasion by forming a 
complex with melanoma chondroitin sulfate proteoglycan, a cell surface proteoglycan expressed early in 
melanoma progression.36
MT3-MMP (originally described by Takino and co-workers22), similar to the related MT-MMPs, is translated as 
a multidomain 607-residue polypeptide chain, consisting of a short signal peptide, a prodomain linked via a 
multiple basic furin cleavage site37 with the catalytic domain, a long linker, a hemopexin-like domain, a 
transmembrane helix and a short cytoplasmic tail. Miyazaki and colleagues later published the slightly different 
cDNA sequence from human brain, which now seems to be generally accepted as the human MT3-MMP.38 
Besides, a soluble human MT3-MMP species formed by alternative splicing has been described.39 MT3-MMP 
bears particularly strong sequence homology with MT5-MMPs.21,22,38 Like MT1-MMP, it is inhibited by TIMP-2 
but not by TIMP-1.40 More efficiently than MT1-MMP does MT3-MMP digest type III collagen into typical 
one-and-three-quarter fragments, while it cleaves type I collagen only at the Gly4-Ile5 bond of the triple helical 
portion of the α2(I) chain.40
Previously, we have determined the structure of the MT1-MMP catalytic domain in complex with TIMP-2 and 
found some characteristic differences such as the MT-specific loop compared with the classical MMPs.25 Here 
we present the crystal structure of the related cdMT3-MMP in complex with the broad spectrum inhibitor 
batimastat. This structure hopefully will help in the rational design of more specific inhibitors, which might be 
useful for differentiating studies on the MT-MMPs. 
Published in: Journal of Molecular Biology (2004), vol. 336, iss.1, pp. 213-225 
Status: Postprint (Author’s version) 
RESULTS AND DISCUSSION 
Overall structure 
The MT3-MMP crystals contain one copy of the complex formed between the catalytic domain of MT3-MMP 
(cdMT3-MMP) and the hydroxamic acid inhibitor batimastat (BB-94) per asymmetric unit. The first five 
residues of this construct (Met1-Tyr120MT3-Ala121MT3-Leu122MT3-Thr123MT3; the superindex MT3 indicates 
MT3 residues numbered according to proMT3-MMP; in the following paragraphs, the superindices pro2, MT1, 
MT2, Ml, M8, T1 and T2 will be used to refer to residues of proMMP-2, MT1-MMP, MT2-MMP, MMP-1, 
MMP-8, TIMP1 and TIMP-2, respectively) are not defined by electron density, although there is enough empty 
space in the crystal to accommodate it in an unconstrained manner. This indicates that the Tyr120MT3 α-amino 
terminus of mature MT3-MMP (and thus, in general, the amino termini of the MT-MMPs) is inherently flexible 
and not involved in a surface-located salt bridge with Asp281MT3 as observed in the collagenases,41 which is 
probably due to the two residues shorter amino terminus of activated MT-MMPs (Figure 1(d)) or the presence of 
the artificial methionine of our construct. Also the last 15 amino acid residues of this construct, which in the full-
length molecule would represent part of the 50-residue inter-domain linker, are not defined by electron density. 
As in other MMPs, the MT3-MMP active-site cleft, which in the standard orientation (Figure 1) extends 
horizontally across the molecule and binds peptide substrates from left to right, separates the smaller "lower 
subdomain" from the larger "upper subdomain". The upper subdomain encompasses a five-stranded, highly 
twisted β-sheet, flanked by three surface loops on its convex side and by two long regular α-helices on its 
concave side (Figure 1(a)). Four of the five β-strands are aligned in a parallel fashion, with only the cleft-sided 
"edge strand" sIV running in opposite direction. This latter strand is linked to the central strand sIII via the 
characteristic "S-shaped double loop" (S-loop), which is fixed via the "structural zinc" (Zn2, Figure 1(a)) and the 
first bound calcium ion (Ca1) to the underlying β-sheet. This S-loop extends into the cleft-sided "bulge", which 
continues into the antiparallel edge sIV, both together forming the alignment segment for binding peptidic 
substrates and inhibitors (see Figures 1 and 2). The end of the sII-sIII connecting segment, also called MT-loop 
due to its unique presence in MT-MMPs (see below), together with the sIV-sV loop sandwich the second 
calcium ion (Ca2). 
After strand sV, the chain passes through the large open sV-hB loop, another segment of high variability (Figure 
1(a)) and a source of specificity42 before entering the long horizontally extending "active-site helix" hB. This 
helix provides the first and the second His residue of the metzincin43 characteristic zinc-binding motif 
(His246MT3 and His250MT3, using the proenzyme numbering of MT3-MMP, together with the "catalytic" 
Glu247MT3; see Figure 1(a) and (d)). Helix hB ends at Gly253MT3, where the chain bends down, provides the 
third zinc ligand (His256MT3), passes the 1,4-tight "Met-turn" Ala262MT3-IIe263MT3-Met264MT3-Ala265MT3,44 
forms with Pro266MT3-Phe267MT3-Tyr268MT3 the outer wall of the Sl'-pocket, and turns through the specificity 
loop back to helix C. 
The overall fold of the MT3-MMP catalytic domain is very similar to that of other MMPs of known structure.          
A total of 151 α-carbon atoms can (within 1.5 Ǻ distance, and with an r.m.s. deviation of 0.64 Ǻ ) be 
superimposed with equivalent α-carbons of MT1-MMP, compared with, for example, 140/147 α-carbons of 
MMP-145/MMP-844 (with rms deviations of 0.66/0.63 Ǻ), i.e. the overall fold is only marginally more similar 
within the MT-MMP subfamily Interesting deviations between MT1- and MT3-MMP are observed in the open 
sV-hB loop, the MT-loop and in the specificity loop (Figure 1(a)). According to the topology-based sequence 
alignment (Figure 1(d)), 68% of the equivalent cdMT3-MMP residues (Tyr120MT3-Gly291MT3) are identical with 
those of MT1-MMP. Among all human MMPs, cdMT3-MMP should, with 80% identity, be most similar to 
cdMT5-MMP21. 
Active-site cleft and batimastat/substrate binding  
The active-site cleft of MT3-MMP is similar to that of MT1-MMP (Figure 2). The S3 pocket of MT3-MMP, 
formed by His208MT3, Tyr210MT3 and Serl97MT3, differs only by a Ser/Thr replacement. Therefore, MT3-MMP 
might show a similar preference for Arg residues at P4 in the absence of P3-Pro residues.46 The hydrophobic S2 
subsite is bordered by Glu255MT3, so that its shallow groove could particularly well accommodate short 
hydrophobic side-chains (such as Cys, see below), but also Arg/Lys at P2; the corresponding Glu248MT1 side-
chain of MT1-MMP (see Figure 2) turns away from the S2 subsite, probably due to the presence of the amino 
terminus of the MT1-MMP catalytic domain co-crystallized with TIMP-2.25 The S1 cleft of MT3-MMP is, as 
that of MT1-MMP, bounded by the flat sides of the side-chains of His208MT3 (one of the ligands of the structural 
zinc) and Phe205MT3 (Figure 2), distinguishing it from the S1 sites of most other MMPs. 
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Figure 2. Stereo view toward the active site, (a) Protein residues and the batimastat inhibitor are shown as white (carbon atoms) and yellow 
(carbon atoms) sticks, respectively. Sulfur atoms are depicted in green, while zinc and calcium ions are represented by pink and blue spheres, 
respectively. The 2Fo-FC simulated annealing omit map of batimastat is contoured at 1σ. (b) and (c) The protein surfaces of MT3-MMP (b) 
and MT1-MMP (c) are shown as solid surfaces, colored according to negative (red) and positive (blue) electrostatic surface potential. The 
catalytic zinc ion is partially exposed (central pink sphere). The bound batimastat inhibitor of cdMT3-MMP is shown with atom colors 
(green carbon atoms), while the bound TIMP-2 is removed from the cdMT1-MMP/TIMP-2 complex.25 In contrast to the continuous S1' tube 
(to the right of the catalytic zinc, (c)) of MT1-MMP, the S1' specificity pocket of cdMT3-MMP is blocked. Figures were made with Swiss 
PDBViewer75 and PoV-Ray /MegaPov. 
 
 
The entrance to the S1' subsite is mostly hydrophobic as in the other MMPs. In contrast to the MT1-MMP, 
however, the MT3-MMP S1'-subsite is not a continuous pore but a limited pocket, bounded at its bottom by the 
Met271MT3 side-chain, which in turn seems to be squeezed between the side-chains of Ile263MT3 and Gln269MT3. 
The equivalent Met264MT1 side-chain of MT1-MMP, packed between similar neighbors, is rotated out of the 
pocket and gives way to the S1' pore, possibly due to lack of a laterally stabilizing Tyr270MT3-Asn234MT3 side-
chain stack as found in MT3-MMP This S1' difference is also reflected in main-chain deviations of the 
embracing specificity loop (Figure 1). We note that the equivalent Arg222M8 side-chain of MMP-844 secludes the 
S1' pocket in a similar manner as observed in MT3-MMP However, a recent MMP-1/inhibitor structure shows 
that long side-chains in S1' are able to displace the occluding Arg214M1 in MMP-1.47 Such flexibility in pocket 
size may also be assumed for MT3-MMP. 
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The S2' subsite is bordered by the protruding benzyl side-chain of Phe205MT3 and the integrated benzyl group of 
Phe267MT3, provided by the bulge-edge segment and by the S1' wall forming segment (see Figure 2(a) and (b)). 
The S2' groove of MT1-MMP, with identical residues, is very similar. With the exception of MT4-MMP, both 
Phe residues are conserved among the MT-MMPs, but are replaced by medium-sized and/or more polar residues 
in the classical MMPs. Thus, the inability of MT3-MMP to cleave, like MT1-MMP, collagen type I into three-
quarter and one-quarter fragments cannot be explained by significant structural differences in the active site cleft, 
but must rather reside in different exosite interactions, or result from a combination of multiple subtle contacts. 
The bound batimastat inhibitor is well defined by appropriate electron density (Figure 2(a)). It coordinates the 
catalytic zinc ion in a bidentate manner via the hydroxyl (distance 2.24 Ǻ) and the carbonyl oxygen (distance 
1.87 Ǻ) of the hydroxamic group. Both oxygen atoms, together with the three ligating His nitrogen atoms              
(Zn distances between 2.02 and 2.16 Ǻ), make up a trigonal-bipyramidal coordination sphere around this zinc 
ion. The peptide-like backbone is bound similar to that observed in the corresponding batimastat complex with 
MMP-8,48 i.e. inserted between the bulge-edge strand and the wall-forming segment, under formation of five 
inter-main-chain hydrogen bonds (distances between 2.79 and 2.98 Ǻ). The thiophene ring, in α-position to the 
hydroxamate moiety, is located above the catalytic zinc, but at a mean distance of 4.5 Ǻ, i.e. too far away for a 
favorable half-sandwich complex. The isopropyl group of batimastat, mimicking a P1' "Leu" side-chain, extends 
into the S1' pocket, still leaving space for a few more solvent molecules. The P2' phenyl ring forms both intra- 
(with the thiophene ring) as well as intermolecular contacts (with Phe205MT3 and Phe267MT3), giving rise to a 
smooth surface spanning the primed region of the cleft. 
The MT-specific loop and its possible involvement in proMMP-2 activation MT3-MMP shares with MT1-MMP 
(and probably with MT2- and MT5-MMP) the characteristic MT-loop that connects strands sII and sIII and 
forms a dominating protuberance on the molecular surface (see Figure 1). Here, 14 residues of the MT3-MMP 
chain between Glu168MT3 and Asp183MT3 replace seven residues in the "classic" MMPs (Figure 1(d)) and the 
non-activating MT4-MMP, and ten residues in MT6-MMP The corresponding loop of MT5-MMP is of identical 
length, whereas the MT-loops of MT1- and MT2-MMP are one residue longer and (in the middle part) of 
different sequence. According to mutation/ deletion/kinetic experiments of Murphy and coworkers,26 the second 
half of the equivalent MT-loop of MT1-MMP is not particularly important, whereas the specifically structured 
N-terminal part seems to be required for efficient activation of proMMP-2. 
It is thus peculiar that just the N-terminal part of the MT3-MMP loop (Glu169MT3-Val170MT3-Pro171MT3-
Tyr172MT3) does not follow the MT1-MMP track (Glu161MT1-Val162MT1-Pro163MT1-Tyrl64MT1) but rather that of 
the classical MMPs, with Pro163MT1 superimposing with Val170MT3 and the Tyrl64MT1 side-chain pointing in a 
different direction than the sequentially equivalent Tyr172MT3, due to an extra bulge at Val162MT1 and differing 
intramolecular packing. It should be mentioned that in both, the MT1-MMP-TIMP-2 structure25 as well as in this 
MT3-MMP-batimastat structure, the MT-loop protrudes into empty intermolecular gaps, relatively unconstrained 
by crystal contacts. The cdMT2-MMP from man has been shown to activate proMMP-2,24 and human and mouse 
MT2-MMPs expressed in COS cells were reported to be active.49 The same group in a later study found, 
however, that human MT2-MMP is defective, but that the cell-associated proMMP-2 activation function can be 
recovered by replacement of the human Glu181MT2-Val182MT2-Pro183MT2-Tyr184MT2-Glu185MT2 by the murine 
MT2-MMP Glu181MT2-Val182MT2-Ser183MT2-Tyr184MT2-Asp185MT2 motif.50 According to TyrMT1 → Ser 
mutation experiments of English and colleagues,26 the contained TyrMT1 residue seems to play some role in the 
proMMP-2 activation, possibly acting as a molecular switch upon docking to proMMP-2. The different phenole 
placement in the MT1- and the MT3-MMP structures does not explain such a function, however, indicating that 
the mechanism of the MT-loop involvement in proMMP-2 activation is more complex. 
The strong correlation of the presence of the MT-loop with the capability of activating proMMP-2, but also the 
mutation experiments mentioned above26 suggest a (direct or indirect) involvement of the MT-loop in proMMP-
2 activation. The MT1-MMP catalyzed proMMP-2 activation starts with a cleavage in the Glu63pro2-Ser64pro2-
Cys65pro2-Asn66pro2*Leu67pro2-Phe68pro2 segment of proMMP-2, i.e. in the loop connecting helices 1 and 2 of the 
prodomain.51 The activation intermediate is then further processed and the final cleavage at Asn109pro2-
Tyr110pro2 through another MMP-2 molecule yields active MMP-2.17,52,53 In both proMMP-2 structures51,54 the 
primary cleavage segment is in a position and conformation not accessible for an attacking MT1-MMP, and the 
residues flanking the primary cleavage site, in particular those C-terminal of it, exhibit enormously high 
temperature factors. This indicates that the cleavage segment is quite flexible and can adapt to an attacking MT-
MMP molecule. Modeling studies show that the primed side segment must partially unfold up to Lys75pro2 and 
adopt an MT-MMP-susceptible conformation55 (see model in Figure 1(b) and (c)), while the relatively rigid non-
primed side Cys60pro2-Cys65pro2 loop must slightly rearrange in order to become attackable by the approaching 
MT-MMP56 Manual docking experiments show that a refolded scissile proMMP-2 segment could insert into the 
Published in: Journal of Molecular Biology (2004), vol. 336, iss.1, pp. 213-225 
Status: Postprint (Author’s version) 
active-site cleft of MT1/3-MMP in a productive manner, under simultaneous touch of helix 2 by the S-loop, 
insertion of the end of helix 1 below the S-loop, and contacts between the MMP-2 segment becoming the N 
terminus and the MT-loop (Figure 3(a)). In this way, the MT-loop could directly or indirectly stabilize the 
encounter complex facilitating proMMP-2 activation. Also other encounter complexes are conceivable, however, 
e.g. under association of both hemopexin-like domains.57 Interestingly, a hemopexin-like domain-dependent 
activation has been described for the MT2-MMP-dependent activation of proMMP-224 and the MT1-MMP-
dependent activation of proMMP-13.58
TIMP-1 docking to MT-MMPs shows obstacles for interaction 
Previously we have shown for a cdMMP-3-TIMP-159 and for a cdMT1-MMP-TIMP-2 complex25 that the wedge-
shaped TIMPs bind with their flexible edge consisting of six loops/segments into the entire active-site cleft of 
their cognate MMPs. The TIMPs mainly interact through their N-term-inal segment and the disulfide connected 
C-D loop, but make a number of contacts through the peripheral sA-sB loop and the two C-terminal loops. A 
superposition of both experimental complexes on the basis of the cdMMPs shows that the relative orientations of 
both cdMMPs and TIMPs differ considerably, what seems to be an inherent, characteristic difference between 
both TIMPs (Figure 3(a)). As a consequence, the C-terminal Cys132T1-Cys137T1 loop of TIMP-1 gets much 
closer to the sV-hB loop of the cognate MMP. In all MT-MMPs, the sV-hB loop is, however, longer for three 
residues (Figure 1(d)) and bulges out toward the approaching TIMP (see Figure 3(a)). Docking studies with 
TIMP-1 and MT3-MMP show that in particular Asn234MT3 and His235MT3 would clash with Leu133T1 and 
Ser134T1. Favorable interactions here would require conformational adaptations, presumably on the cost of free 
energy of binding. 
On the other hand, the favorable hydrophobic contacts between the TIMP-2 patch formed by Ile157T2 and 
Trp151T2 with Phe260MT1 (Phe267MT3) would not be possible with TIMP-1 (Figure 3(b)). In our modeled TIMP-
1-MT3-MMP complex, only the hydrophobic part of the Glu156T1 side-chain would get into contact with 
Phe267MT3 (Phe is conserved in all human MT-MMPs except for MT4-MMP, where it is a Tyr). Furthermore, an 
MT1/3-MMP complex with TIMP-1 would lack the favorable interactions made by the extended sA-sB loop of 
TIMP-2, which in the MT1-MMP-TIMP-2 complex slots into the surface groove left by the MT-loop, the side-
chains of Asp212MT1 and Phe250MT1, and the S-loop of MT1-MMP25 The importance of these interactions for the 
MT-MMP-TIMP-2 complex stability is shown by the 40-fold reduction in the apparent Ki value of the 
Tyr36T2Gly sA-sB loop tip mutants (of N-TIMP-2) for association with MT1-MMP18 These interactions 
mediated through the sA-sB loop might also pull the "left" side of TIMP-2 (Figure 3(a)) towards the MT1-MMP 
molecule, thus preventing the approach of the "right" side, which in the modeled TIMP-1 complex shows clashes 
(see above). In summary, the crystal structures of MT1- and MT3-MMP are not in agreement with the favorable 
binding of TIMP-1, somewhat explaining the extremely low association reaction/affinity. 
When we had completed this manuscript, we became aware of a new paper describing a triple mutant rendering 
TIMP-1 as active against MT1-MMP as other TIMPs.60 The critical replacement is that of Thr98T1, which in our 
model faces a solvent-exposed cavity formed by the molecular MT1/3-MMP-TIMP-1 interface and just touches 
the side-chains of Pro266MT3 and Phe267MT3 (see Figure 3(b)), by Leu98T1. In essence, the longer leucine side-
chain in this position may interact more intimately with Pro266MT3 and may also touch His256MT3 and 
Phe267MT3, thus forming a much better hydrophobic interaction with MT1/ 3-MMP Interestingly, Thr98T1, which 
is located in the E-F loop of TIMP-1, is (because of the different loop conformation, but also due to different 
chain lengths) topologically equivalent to Leu100T2 (Figure 3(b)).25 This makes the favorable effect of the Thr → 
Leu replacement somewhat conceivable, but not its extent. The multiple contacts of the inherently flexible TIMP 
loops make the assessment of replacement effects extremely difficult. 
This mutant is remarkable in that it shows that small apparently insignificant changes in the TIMPs can shift the 
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Figure 3. (a) Model of the encounter complex between cdMT3-MMP and proMMP-2. MT3-MMP is shown as orange ribbon with the MT-
loop in surface representation and the zinc and calcium ions in pink and green, respectively. The MT-MMP cleavage site of the prodomain 
(grey) of proMMP-2 (PDB code: 1CK7) was modeled into the active site of MT3-MMP (see the text). The catalytic domain, the fibronectin 
type-II repeats, the linker and the hemopexin-like domain are shown in green, purple, blue and yellow, respectively. The Figure was made 
with DS ViewerPro (Accelrys Inc.). (b) and (c) Stereo view of the experimental complex formed between cdMT1-MMP (blue) and TIMP-225 
(gray) and a modeled (hypothetical) complex formed between cdMT3-MMP (yellow) and TIMP-1 (red). The position of TIMP-1 was 
obtained by superimposing the experimental cdMMP-3/TIMP-1 complex59 on the cdMT1-MMP/TIMP-2 complex on the basis of the MMPs. 
Finally, cdMMP-3 was deleted and cdMT3-MMP was superimposed on cdMTl-MMP (b) both complexes are shown with their front side, the 
active site clefts point toward the bottom. The sA-sB and sG-sH loops of TIMP have been labeled, and the sV-hB loops and the MT-loops of 
the MT-MMPs have been indicated. The Figure has been made with Swiss PDBViewert†75 (c) Stereo view of the close-up of the central 
TIMP binding site of the experimental cdMTl-MMP (blue)-TIMP2 (gray) complex and the modeled cdMT3-MMP (orange)-TIMP-l (green) 
complex. The Figure was made with DS ViewerPro (Accelrys Inc.). 
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MATERIALS AND METHODS 
Cloning, expression, refolding and purification of cdMT3-MMP 
For the PCR amplification of the cDNA encoding cdMT3-MMP (from nucleotide 470 to nucleotide 1042), the 
MT3-MMP plasmid, kindly provided by H. Sato, was used as a template together with two synthetic nucleotide 
primers designed according to the known cDNA sequence (Accession number D50477).22 The sense primer 5'-
GGAATTCATATGTATGCATTGAC AGGACAGAA-3' and the antisense primer 5'-AA 
CTGCAGCTAGCGGTGTGG GGGCACTGT-3' were designed to incorporate Nde I or Pst I sites (underlined) 
and an N-terminal methionine, respectively. The amplified PCR fragment was digested with these restriction 
enzymes and cloned into the pCTBR2 vector.61 The resulting plasmid was called pT7cdMT3. 
BL21 (DE3) cells were transformed with the pT7cdMT3 plasmid and grown as described.62 The cdMT3 
expression was induced by adding 0.5 mM iso-propyl-β-D-galactopyranoside for three hours when the cell 
density reached an A600 of 0.6. The cells were harvested by centrifugation and resuspended in lysis buffer (50 
mM Tris-HCl (pH 7.5), 100 KCl, 0.1% Brij). The lysate was sonicated and the inclusion bodies were collected 
by centrifugation, and washed three times each with 50 mM Tris-HCl (pH 7.5), 2 M NaCl, 0.1% Brij, and with 
50 mM Tris-HCl (pH 7.5). 
Washed inclusion bodies were solubilized by stirring for two hours at 22°C in 50 mM Tris-HCl (pH 8.5), 8 M 
urea, and 0.1% β-mercaptoethanol. The denaturation mixture was dialyzed for four hours each at 4°C against a 
50mM Tris-HCl (pH 8.5) buffer containing 100 mM NaCl, 10 mM CaCl2, 100 µM ZnCl2, and urea at 
progressively decreasing concentrations in order to slowly eliminate urea. Additional dialyses were performed 
for 24 hours against Tris assay buffer (50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM CaCl2, 1 µM ZnCl2). 
The refolded cdMT3 (with residues Metl-Tyrl20MT3-...-Pro307MT3)38 was concentrated by ultra-filtration (3-kDa 
cutoff, YM3 membrane, Amicon), and the precipitate was removed by centrifugation after incubation overnight 
at 4°C. The supernatant was subjected to a HitrapQ anion-exchange column (5 ml, Pharmacia) equilibrated with 
50 mM Tris-HCl (pH 7.5) and 5 mM CaCl2, and eluted with a NaCl gradient (0-500 mM) in 50 mM Tris-HCl 
(pH 7.5), and the peak fractions containing the homogenous cdMT3 were pooled. 
Crystallization, data collection, and structure refinement 
The human cdMT3-MMP-batimastat complex was crystallized using the sitting-drop vapor-diffusion technique. 
An aliquot of 1 µl protein/inhibitor solution (50 mM Tris-HCl (pH 8.5), 100 mM NaCl, 5 mM CaCl2, containing 
10 mg/ml cdMT3-MMP and 0.5 mg/ml batimastat) was mixed with 1 µl reservoir buffer (100 mM Tris-HCl (pH 
8.7), 1.1 M K/Na-tartrate) and concentrated against the reservoir at room temperature. Batimastat/ BB-94, a 
broad spectrum MMP-inhibitor with a Ki for MMP-1, -2 and -3 of about 1 nM,63 was a generous gift from 
British Biotech. After a few days, brick-like crystals (200 µm X 200 µm X 100 µm) formed belonging to the 
tetragonal space group P4322 (Table 1). With one monomer of 21.3 kDa per asymmetric unit, these crystals have 
a solvent content of 47% (v/v). 
After adding 20% (v/v) glycerol to the mother liquor, a first data set to 2.2 A resolution was collected from a 
crystal cooled to 100 K in a nitrogen stream on a MAR-Research (Hamburg, Germany) 345 image plate detector 
by using monochromatized CuKα radiation produced by a conventional rotating anode. The data set was 
processed with the HKL package.64 The orientation and position of the human cdMT3-MMP-batimastat complex 
was determined by Patterson search techniques using the program AMoRe65 and the catalytic domain of human 
MT1-MMP (PDB accession code 1BQQ; residues: Πell4-Ser287)25 as a search model. A second dataset to 1.80 
A resolution was collected with a flash-cryocooled crystal at a wavelength of 1.050 A at the beamline BW6 of 
the Deutsches Elektronen Synchrotron (DESY) in Hamburg, Germany, employing a Mar Research CCD 
detector. The structure of the human cdMT3/batimastat complex was refined with XPLOR66 using the Engh & 
Huber parameters.67 The Rfree validation was based on a subset of 4.9% of the reflections omitted during the 
entire refinement procedure. In later stages of refinement, the maximum-likelihood algorithm implemented in the 
program CNS68 was used. Each round of refinement was followed by manual model rebuilding using the 
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Table 1. X-ray data and final refinement statistics 
Crystal cell constants: a = 51.21 Ǻ, b = 51.21 Ǻ, c = 149.37 Ǻ, 
α, β, γ = 90°  
Space group: tetragonal P4322 
Resolution (Ǻ) 16.60-1.80 
Mosaicity (°) 0.4 
Reflections measured 119,029 
Reflections unique 18,455 
I / σ, overall 5.5 
I /σ (1.9-1.8 Ǻ) 2.2 
Rmerge (%)a/ overall 8.3 
Rmergε (%)a, (1.9-1.8 Ǻ) 32.7 
Completeness (%), overall 96.7 
Completeness (%), (1.9-1.8 Ǻ) 91.1 
Number of non-hydrogen protein atoms 1346 
Number of inhibitor atoms 32 
Number of water molecules 116 
Reflections used for refinement 17,555 
R valueb (%) 20.8 
Rmergec (%), from 4.9% of the data 23.6 
R.m.s. standard deviation  
Bond lengths (Ǻ) 0.014 
Bond angles (deg.) 1.712 
R.m.s. Bd (Ǻ2) 3.907 
Mean B factor, protein main-chain (Ǻ2) 28.7 
Mean B factor, protein side-chain (Ǻ2) 31.1 
Mean V factor, batimastat (Ǻ2) 20.5 
Mean B factor, solvent (Ǻ2) 37.3 
Φ, Ψ angle distributione  
In core regions 119 (92.2%) 
In additionally allowed regions 10 (7.8%) 
 
 
The final refinement cycles with REFMAC71 led to a model with an R-value of 20.7. The final model consists of 
segment Gly124MT3-...-Pro292MT3 (cdMT3-MMP), the batimastat inhibitor, 115 water molecules, and two zinc 
and two calcium ions (Table 1). Except for discontinuous electron density in the MT-specific loop region 
Leu175MT3-Gly178MT3 and the sV-hB region His235MT3-Asp236MT3, the cdMT3-MMP main-chain can be fully 
traced in continuous electron density. All main-chain angles of non-glycine residues fall into the most favored or 
allowed regions of the Ramachandran plot as defined by PROCHECK.72
Protein Data Bank accession code 
The structure of the cdMT3-MMP/batimastat complex reported here has been deposited in the RCSB Protein 
Data Bank (PDB code: 1RM8). 
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